Development of nano alpha-ketoglutarate nebulization formulation and its pharmacokinetic and safety evaluation in healthy human volunteers for cyanide poisoning

2011 ◽  
Vol 31 (3) ◽  
pp. 436-442 ◽  
Author(s):  
Shaheen Sultana ◽  
Thakuri Singh ◽  
Farhan Jalees Ahmad ◽  
Aseem Bhatnagar ◽  
Gaurav Mittal
Keyword(s):  
Safety Evaluation ◽  
Cyanide Poisoning ◽  
Healthy Human ◽  
Human Volunteers

Development of atropine sulphate nasal drops and its pharmacokinetic and safety evaluation in healthy human volunteers

2009 ◽  
Vol 27 (2) ◽  
pp. 206-211 ◽  
Author(s):  
Sheetal Rajpal ◽  
Gaurav Mittal ◽  
Ruchi Sachdeva ◽  
Mitrabasu Chhillar ◽  
Rashid Ali ◽  
...  
Keyword(s):  
Safety Evaluation ◽  
Atropine Sulphate ◽  
Healthy Human ◽  
Human Volunteers

scholarly journals Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog

2014 ◽  
Vol 6 ◽  
pp. OED.S12445 ◽  
Author(s):  
Yoshimi Niwano ◽  
Atsuo Iwasawa ◽  
Masahiko Ayaki
Keyword(s):  
Ocular Surface ◽  
Safety Evaluation ◽  
In Vitro Cytotoxicity ◽  
Conjunctival Hyperemia ◽  
Healthy Human ◽  
Upper Eyelid ◽  
Human Volunteers ◽  
Preservative Free ◽  
Viability Score

In vitro cytotoxicity of tafluprost, which is the most recently developed anti-glaucoma prostaglandin (PG) analog, in ocular surface cells is addressed in comparison with other PG analogs. Irrespective of cell lines and models, the cytotoxicity of anti-glaucoma PG eyedrops was primarily related to the concentration of benzalkonium chloride (BAK) contained in the eyedrops as a preservative. Accordingly, preservative-free tafluprost was apparently less cytotoxic than BAK-preserved PG analogs. Furthermore, our study for cytotoxicity assays on ocular cells, conducted by comprehensive investigations covering a variety of concentrations and treatment times, which is termed the cell viability score (CVS) system, demonstrated that 0.001% BAK-preserved tafluprost was not cytotoxic, and suggested that tafluprost may even reduce the cytotoxic effect of BAK. It has been reported that adverse reactions associated with tafluprost in healthy human volunteers and patients with glaucoma include conjunctival hyperemia, eyelid pigmentation, eyelash bristles, and deepening of upper eyelid sulcus. Nonetheless, most clinical studies have demonstrated that not only preservative-free tafluprost but also BAK-preserved tafluprost is well tolerated and safe in patients with glaucoma and ocular hypertension.

Gastroretentive Floating Capsules of Risedronate Sodium: Development, Optimization, in vitro and in vivo Evaluation in Healthy Human Volunteers

2015 ◽  
Vol 8 (2) ◽  
pp. 2835-2842
Author(s):  
Bhikshapathi D. V. R. N. ◽  
Arun Kumar Jarathi ◽  
Suresh Gande ◽  
Viswaja Medipally ◽  
Ramesh Bomma
Keyword(s):  
Drug Release ◽  
Sustained Release ◽  
Zero Order ◽  
Wet Granulation ◽  
Capsule Formulation ◽  
In Vivo Evaluation ◽  
Healthy Human ◽  
X Ray ◽  
Human Volunteers

Background and the purpose of the study: Risedronate sodium inhibits osteoclast bone resorption and modulates bone metabolism. Risedronate has a high affinity for hydroxyapatite crystals in bone and is a potent antiresorptive agent. In the present investigation efforts were made to improve the bioavailability of risedronate sodium by increasing the residence time of the drug through sustained-release matrix capsule formulation via gastroretentive mechanism. Capsules were prepared by wet granulation technique. The influence of gel forming agents, amount of risedronate and total weight of capsules on physical properties, in vitro buoyancy, drug release, FTIR, DSC, X-ray studies were investigated. The release mechanisms were explored and explained by applying zero order, first order, Higuchi and Korsmeyer equations. The selected formulations were subjected to stability study at 40 °C/75% RH, 25 °C/60% RH for the period of three months. For all formulations, kinetics of drug release from capsules followed Higuchi’s square root of time kinetic treatment heralding diffusion as predominant mechanism of drug release. Formulation containing 25 mg HPMC K4M and 75 mg HPMC K100 LV (F-8) showed zero order release profile. There was no significant change in the selected formulation, when subjected to accelerated stability conditions over a period of three months. X-ray imaging in six healthy human volunteers revealed a mean gastric retention period of 5.60 ± 0.77 hrs for the selected formulation. Stable, sustained release effervescent floating capsules of risedronate sodium could be prepared by wet granulation technique.  

Synthetic Nanoclay Gels Do Not Cause Skin Irritation in Healthy Human Volunteers

2021 ◽  
Author(s):  
Luciana E. Bostan ◽  
Claire E. Clarkin ◽  
Mohamed Mousa ◽  
Peter R. Worsley ◽  
Daniel L. Bader ◽  
...  
Keyword(s):  
Skin Irritation ◽  
Healthy Human ◽  
Human Volunteers

Some Effects of Nalorphine on the Behaviour of Healthy Human Volunteers

1957 ◽  
Vol 103 (433) ◽  
pp. 850-854 ◽  
Author(s):  
D. A. Cahal
Keyword(s):  
Healthy Human ◽  
Human Volunteers

Some workers have claimed that nalorphine is as potent an analgesic as morphine and does not lead to addiction.

Short‐Term Repeatability of in Vivo Cardiac Intravoxel Incoherent Motion Tensor Imaging in Healthy Human Volunteers

2021 ◽  
Author(s):  
Xiu‐Shi Zhang ◽  
En‐Hui Liu ◽  
Xin‐Yu Wang ◽  
Xin‐Xiang Zhou ◽  
Hong‐Xia Zhang ◽  
...  
Keyword(s):  
Intravoxel Incoherent Motion ◽  
Short Term ◽  
Healthy Human ◽  
Human Volunteers
Sign in / Sign up

Export Citation Format

Share Document